AVDL

Avadel Pharmaceuticals plc

15.63 USD
+0.14 (+0.90%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avadel Pharmaceuticals plc stock is down -10.07% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 25 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 May 17:59 21 Jun, 2024 20.00 PUT 125 44
06 May 13:57 17 Jan, 2025 20.00 CALL 100 3275
06 May 14:04 17 Jan, 2025 17.50 CALL 100 17335
07 May 16:24 17 Jan, 2025 20.00 CALL 100 3376
07 May 19:25 17 May, 2024 20.00 CALL 1513 1913
09 May 14:17 21 Jun, 2024 15.00 PUT 1500 304
10 May 18:47 17 Jan, 2025 20.00 CALL 150 3092
10 May 19:52 21 Jun, 2024 15.00 CALL 432 1489
13 May 14:04 21 Jun, 2024 15.00 PUT 1500 1651
13 May 16:50 21 Jun, 2024 22.50 PUT 100 234

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

  • HC Wainwright & Co.
    Thu May 9, 15:24
    buy
    confirm
  • Craig-Hallum
    Thu May 9, 11:43
    buy
    confirm
  • Needham
    Thu May 9, 07:17
    buy
    confirm
  • Needham
    Wed May 8, 09:15
    buy
    confirm